Vanderbilt Vaccine Center (VVC)

June 8, 2022

Research probes cause of acute flaccid myelitis in children

Research that began at Vanderbilt University Medical Center has found evidence that a viral infection followed by a “robust” immune response is the cause of a polio-like paralyzing illness in children called acute flaccid myelitis (AFM).

By Bill Snyder
March 31, 2022

Crowe receives national award for COVID antibody research

Vanderbilt’s James Crowe Jr., MD, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19.

By Bill Snyder
Lawrence Marnett, PhD, left, and Jennifer Pietenpol, PhD, right, presented 2021 Research Staff Awards to Kimberly Newsom, second from left, Tracie Baker, CCRP, and Pavlo Gilchuk, PhD.
March 9, 2022

Research Staff Awards honor those who help drive science forward

Laboratory and administrative personnel at Vanderbilt University Medical Center were honored March 4 for research excellence during the 18th annual Research Staff Awards Ceremony.

By Bill Snyder
February 17, 2022

Pandemic leads to broader use of monoclonal antibodies

Antiviral drugs and coronavirus-fighting monoclonal antibodies, including those discovered at Vanderbilt University Medical Center, remain crucially important in the continuing fight against COVID-19.

By Bill Snyder
January 20, 2022

Omicron evades some but not all monoclonal antibodies: study

A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.

By Bill Snyder
Cody Stubblefield, RN, gives the first of two injections of an antibody combination to Caroline Davis to protect her from COVID-19.
December 23, 2021

Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness

On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.

By Bill Snyder
December 9, 2021

Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization

The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which  protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
By Bill Snyder
December 2, 2021

Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms

By Bill Snyder
November 18, 2021

Seven from VUMC among most highly cited researchers

Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
By Bill Snyder
October 28, 2021

VUMC researchers a step closer to broad ebolavirus protection

By Bill Snyder
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
By Bill Snyder
September 8, 2021

VUMC antibodies help neutralize two deadly viruses: study

Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
By Bill Snyder
1 2 3 4 5 … 14